TPST Tempest Therapeutics, Inc.
$0.81▲ +1.13%
Healthcare
Other
After hours
$0.82▲ +1.02%
Sep 11, 7:55 PM ET
Volume 766.6K
Avg Volume (10D) 165.7K
Key Metrics & Fundamentals
Market Cap
$13.43M
P/E Ratio
–
Div Yield
–%
52W Range
0.76 - 12.23
% vs 50 MA
-18.73%
% vs 200 MA
-57.47%
RSI-14
32.8
MACD Histogram
-0.0300
Beta (1Y vs SPY)
1.31
Free Cash Flow
-$2.78M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$5.18M
COGS
–
Operating Exp
$5.25M
Operating Income
-$5.25M
EBIT
-$5.25M
Pretax Income
-$5.24M
Net Income
-$5.24M
EPS (Diluted)
-0.34
Price & Volume History
Loading chart…
Recent News
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
GlobeNewswire · Sep 11, 2026 12:00 PM
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 8, 2026 12:30 PM
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 13, 2026 8:25 PM
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
GlobeNewswire · Jul 21, 2026 11:00 AM
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
GlobeNewswire · Jul 15, 2026 11:00 AM
Rani Therapeutics Names Nicholas Maestas CFO
MT Newswires · Jun 29, 2026 12:55 PM
Tempest Therapeutics Registers 2.43 Million Shares for Resale
MT Newswires · Jun 26, 2026 8:47 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See TPST's money flow as a full page
Social Sentiment
Avg +0.70 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.